Inhibiting mitogen-activated protein (map)/erk kinase (mek)1 and mek2 and related methods of treatment

Abstract

Methods of treating cancer, including RAS-mutated cancers and certain RAF-mutated cancers, are provided, comprising the administration of a therapeutically effective amount of dual-MEK inhibitor with a short plasma half-life that inhibits both the phosphorylation of mitogen-activated protein kinase kinase 1 or 2 (pMEK) and the phosphorylation of mitogen-activated protein kinase 1 or 2 (pERK), wherein the dual-MEK inhibitor is administered to the patient in certain dose amounts that achieves a Cmax effective to inhibit pERK and pMEK and with an interval between consecutive doses that is at least about certain times the plasma half-life of the dual-MEK inhibitor.

Dependencies are inferred from the claim text.